Ignite Creation Date:
2024-06-16 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06428500
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2024-05-16
Brief Title:
QTX3046 in Patients With KRAS G12D Mutations
Sponsor:
Quanta Therapeutics
Organization:
Quanta Therapeutics
Study Overview
Official Title:
A Phase 1 Trial Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None